Pharmaceuticals announced moderated poster presentations of new data from the HELIOS-B Phase 3 clinical trial, which evaluated ...

AI tools that analyze echocardiograms and electrocardiograms can identify those at higher risk of heart disease-related death, a study at the ACC meeting showed.

Researchers at the American College of Cardiology's annual meeting used proteomic approaches to uncover dysregulated signaling pathways in the disease.

Over the last three years, the FDA has approved six new hemophilia drugs, including three gene therapies. | Over the last ...

The Food and Drug Administration (FDA) has approved Amvuttra ® (vutrisiran) for the treatment of the cardiomyopathy of ...

CM. Read why NTLA stock has potential with upcoming 2025 data and a growing $12B market for Transthyretin Amyloidosis.

Based on the terms of the agreement, BridgeBio will receive a $30 million milestone payment upon approval in Japan, as well ...

The FDA recently approved the first treatment in nearly 30 years for acute stroke, and the agency also approved a novel drug ...

In the Japanese Phase 3 study, 0% mortality was reported over the 30-month treatment period and acoramidis was well-toleratedThe approval was ...

Amvuttra operates via RNA interference (RNAi), a groundbreaking technology that inhibits the production of the TTR protein in ...

President Donald Trump continues to warn of tariffs on the pharmaceutical industry; Susan Monarez replaces Dave Weldon as CDC ...

BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) had its price target increased by equities researchers at JPMorgan Chase & ...